Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say
Executive Summary
Merck has held a monopoly on the dipeptidyl peptidase-4 inhibitor market for type 2 diabetes since launching Januvia (sitagliptin)in 2006 - a franchise that's now approaching blockbuster status - but within the next year it could be sharing scripts with two new rivals